The use of liquid biopsies as a non-invasive method for early recognition and management of cancer is rapidly evolving. Circulating tumor cells (CTCs), cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA) are potential biomarkers for cancer. This review identifies the diagnostic and treatment monitoring value of CTC-, cfDNA-, and ctDNA-based biomarkers in endocrine neoplasia. Methods: A search was performed in Embase and PubMed databases from September to November 2018. The search included liquid biopsies measuring CTC, cfDNA, ctDNA, and endocrine neoplasia terms. Articles within the last 5 years featuring original data in regard to detection of biomarkers from endocrine patient blood samples were retained. Results: The search identified 622 unique references. Of these, 65 articles were selected for inclusion which assessed patients with adrenal, ovarian, pancreatic, testicular, and thyroid tumors, most of which were thyroid. No publications were identified for parathyroid and pituitary neoplasms. Conclusions: There is a large variation in mutation detection and wide estimates of sensitivity and specificity indicating that liquid biopsies are not currently useful as a surrogate for tissue-based biopsy for diagnosis of endocrine neoplasms. Once a tumor is diagnosed and the mutations defined, liquid biopsies may be useful for monitoring the clinical course.
For a comprehensive list of publications in each database, search terms for liquid biopsy, "cell-free DNA" or "cfDNA", "circulating tumor cells" or "CTCs", "circulating tumor DNA" or "ctDNA" were used. A broad search was conducted for endocrine neoplasia which included endocrine neoplasia, endocrine tumors, or endocrine cancer. The search was then expanded to search under individual endocrine organ terms for "adrenal tumors", "ovarian endocrine tumors", "pancreatic islet cell tumors", "pancreatic neuroendocrine tumors", "parathyroid tumors", "pituitary tumors", "testicular tumors", and "thyroid tumors".
Two reviewers conducted the screening. From the database search results, abstracts were first reviewed for studies that included serum or plasma samples from patients with endocrine cancer and reported analysis of CTC, cfDNA, or ctDNA. Studies which included other types of biomarkers, such as microRNA, in addition to CTC, cfDNA, or ctDNA were included. Studies assessing patients with several cancer types were included if at least one type of cancer studied was of endocrine origin.
Those featuring original data relating to absolute numbers in regard to detection of circulating biomarkers using a liquid biopsy for diagnosis and/ or treatment monitoring in patients with endocrine cancer were retained for assessment. Articles cited in original reports and review articles identified in the database search were added to the review. Comments, letters, editorials and expert opinions, and abstracts that did not specify quantitative results were excluded. Articles including blood samples from adult human study populations were retained for review (publications of adrenocortical tumors in pediatric patients were excluded during the screening). Studies that investigated only tumor tissue, cell lines, and lavage fluid DNA with no liquid biopsy sample as part of the study were excluded.
Some studies that measured tumor RNA in serum or plasma were included.
Using the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) flowchart, the relevant manuscripts were selected for full-text review ( Figure 1 ). Data extracted from each full-text publication or abstract were as follows: authors and publication year, endocrine organ, biomarker type, genes targeted, cases and controls (if applicable), time of sampling, study aims, and results. For study results, our primary outcome of interest was the prevalence of detection and/or estimate of diagnostic accuracy and area under the curve (AUC) cut-off values, sensitivity, and specificity as well as prevalence by cancer stage. We calculated sensitivities and specificities if these were not specifically determined and the manuscripts included sufficient individual patient results.
Results
A total of 622 unique publications were assessed for eligibility. Of those, 123 full-text articles were reviewed and 65 publications were identified for inclusion ( Figure 1 ). Of these, 16 were abstracts that report quantitative data and the remaining were peer-reviewed manuscripts. The primary reason studies were excluded was due to not evaluating patients with endocrine neoplasia. For example, most of the ovarian cancer articles studied epithelial ovarian cancer subtypes and we aimed to assess germ cell or sex-cord tumors. Recent reviews of liquid biopsies and epithelial ovarian cancers were identified in our search. [15] [16] [17] [18] [19] [20] [21] Some studies in patients with ovarian cancer did not report histopathology, and we included these in this review with indication of ovarian cancer type not specified. Similarly, we excluded studies that assessed liquid biopsies only in patients with pancreatic ductal adenocarcinoma and restricted our results to studies that included patients with pancreatic NETs (pNETs), bronchopulmonary NETs (BPNETs), and gastroenteropancreatic NETs (GEPNETs).
By cancer type, the majority of publications studied liquid biopsies in thyroid cancer (n=32) followed by endocrine ovarian cancer (n=13) and NETs (n=12). Four papers included patients with adrenal and testicular cancers. No publications were identified in our search for parathyroid and pituitary neoplasms. Table 1 summarizes each publication categorized by tumor site (adrenal, ovarian, NETs, and testicular) and Table 2 includes thyroid cancer publications. Table 3 summarizes the sensitivities and specificities for CTCs, cfDNA/ctDNA, and other biomarkers by endocrine tumor site.
Adrenocortical carcinomas Circulating tumor cells
No data available
Circulating cell-free DNA or circulating tumor DNA Assays measuring mutations in cfDNA 22 and ctDNA 23 showed sensitivities of 33.0% and 25.0%, respectively for detecting the mutations in plasma that were present in the primary tumor samples. Though limited, findings from these studies suggest metastatic adrenocortical carcinomas secrete ctDNA, and when detected, the ctDNA mutations followed tumor dynamics.
However, Creemers et al. 22 were unable to detect mutations in the cfDNA from two of three patients with known cancer tissue. Similarly, ctDNA was not detected in some patients with progressive disease with large tumor burdens. 23 Other Perge et al. 24 and Salvianti et al. 25 measured levels of microRNAs in plasma. Both miR483 and miR483-5p plasma levels showed relatively high sensitivities (83.0-88.9%) and specificities (63.6-100.0%) at varying cut-off Ovarian endocrine tumors
Circulating tumor cells
Three studies measuring expression of epithelial cell adhesion molecule (EpCAM) in CTCs showed varying results. 26, 30, 33 No CTCs were detected in two patients with stromal ovarian tumors studied by Lou and coworkers. 30 Banys-Paluchowski et al. 26 reported a detection prevalence of 43 .3% (26/60) and Obermayr et al. reported that all patients with ovarian cancer were CTC-positive. 33 Circulating cell-free DNA or circulating tumor DNA Seven studies measured variant detection in ctDNA. [27] [28] [29] 31, 35, 37, 38 In studies that included both tumor tissue-based biopsy mutation detection and ctDNA, ctDNA was detected at a lower frequency than tumor tissue. [27] [28] [29] [30] [34] [35] [36] [37] Wang et al. studied the use of a novel assay with the Papanicolaou (Pap) test fluid to increase sensitivity for ovarian cancers and reported that ctDNA was found in 43.0% of the patients in a plasma sample alone and when plasma and Pap brush samples were both tested, the sensitivity for ovarian cancer increased to 63.0%. 37 Two patients with endocrine ovarian cancer were included in this study, but plasma samples were not taken in either of these samples. Both patients had negative Pap and
Tao brush results and were negative for somatic and aneuploidy using the assay. However, the patient with a sex cord-like tumor had KRAS and PIK3CA mutations identified in the primary tumor tissue. 37 Detection of germline and somatic mutations in ctDNA in three of five endocrine ovarian cancers were observed, 34 as well as in copy number alterations in a patient with dysgerminoma. 32 One study did not find a significant difference between cfDNA in two patients with teratomas compared to healthy controls. 36 Pancreatic, bronchopulmonary, and gastroenteropancreatic neuroendocrine tumors
Two studies reported a CTC detection rate between 38.0-54.5% in patients with pNETs using the CellSearch ® assay (Menarini Silicon Biosystems, Inc., Huntington Valley, Pennsylvania, USA). 47, 50 Circulating cell-free DNA or circulating tumor DNA 54 The presence of CTCs significantly correlated with tumor histology, stage of disease, and tumor marker levels in blood serum in these patients. 54 Circulating cell-free DNA or circulating tumor DNA No data available.
Other A study identified 20 candidate genes in microRNA of patients with seminoma using microarray analysis by measuring copy number before and after surgery. 53 Thyroid cancer
Overall, 11 of the 32 studies measured CTCs in patients with thyroid cancer.
A prospective study screened subjects with an increased risk of cancer and CTCs were detected in half (132/265) of the screened participants; of those, 24 subjects (20.0%) had cancer confirmed within the following year.
Five additional known patients with thyroid cancer had detectable CTCs. 78 Ehlers 64 Of note, in a study comparing detection of BRAF V600E mutation in ctDNA to imaging in patients with BRAF-positive anaplastic thyroid cancer, concordance was 94.0-100.0% in patients with regression and stable disease but only 47.0% in patients with progressive disease. 63 All patients with radioactive iodine refractory differentiated thyroid carcinoma with BRAF V600E mutation in ctDNA at baseline had undetectable levels after three dabrafenib ± trametinib treatment cycles. 67 A multigene panel reported an overall 67.0% ctDNA detection rate, which was highest in patients with metastatic disease (79.0%) compared to local recurrence (33.0%) or no macroscopic disease (0%). 56 In a 70-gene assay (Guardant360 ® , Guardant Health Inc., Redwood City, California, USA), overall concordance was 72.0% in 12 patients with anaplastic thyroid cancer without treatment but 100.0% concordance for the presence of BRAF V600E and NRAS mutations. 80 Patients with surgery or treatment prior to study (n=7) had 6.0%
concordance and there was no concordance between tissue and ctDNA in patients without active disease at the time of the study. 80 In patients with advanced malignancy, the Guardant360 assay had high specificity, but low sensitivity, with a diagnostic accuracy range of 82.0-89.0% for concordance of genomic alterations obtained from tissue biopsies and plasma cfDNA. 58 Lastly, a retrospective study measured ctDNA using the Guardant360 assay in 88 patients with head and neck squamous cell carcinoma in which TP53
and PIK3CA were the most common mutations identified, and 75.0% of patients with thyroid cancer had actionable mutations. 75 Studies which measured RET M918T mutation in ctDNA in patients with medullary thyroid cancer, reported 32.0% 60 and 61.5% 57 mutation detection in positive tissue mutation samples with a calculated 34.5% sensitivity and 84.2% specificity for distinguishing distant metastases. 60 Busaidy et al. reported emergence of RET V804M mutation after tyrosine kinase inhibitor exposure. 57 Other A study measuring circulating tumor-associated microparticles (taMPs) included 43 patients with thyroid nodules and found EpCAM + taMPs significantly increased in this group compared to healthy controls. 81 Using blood sampling and tissue biopsy. 88 CtDNA detection is increased in higher stage cancers, especially when comparing metastatic to localized disease. 9 In patients with adrenocortical carcinomas, ctDNA was not detected in some patients with progressive disease with large tumor burdens, 23 and it remains unclear whether ctDNA detection was negative due to assay sensitivity limitations or if adrenocortical carcinoma does not shed large quantities of ctDNA. Correspondingly, somatic variants detected in ctDNA may not be released from a tumor, but rather originate from clonal hematopoiesis. 4, [88] [89] [90] [91] Increased levels of cfDNA are found in individuals with inflammatory or benign conditions, healthy individuals, and associated with aging, 4, 91 which may result in false-positive cases with ctDNA detection.
There were few studies identified for adrenal and testicular neoplasms, which limits the comparisons that can be made. Additionally, sample sizes were generally low. Of the three studies measuring CTCs in patients with testicular cancer, two are case reports. 51, 52 Due to the small number of patients in the majority of the clinical studies included in our analysis, especially when stratified by endocrine tumor type and stage, it is difficult to determine if assay sensitivities are useful for earlier or late stages or if there is no difference. For adrenal neoplasms, there is low sensitivity for differentiating benign adrenocortical adenoma from adrenocortical carcinoma using ctDNA, 22, 23 but microRNAs may be useful for monitoring therapy response in both high-and low-risk patients. 25 Of the thirteen studies identified in our search studying endocrine ovarian cancer, five did not specify histopathology, 26 56, 82 It is unclear how liquid biopsies compare to assays for tumor-associated proteins in other endocrine neoplasms as well.
For example, serum ctDNA samples did not show a significant difference between patients with granulosa cell tumor and healthy controls, yet cancer antigen 125 (CA125) levels were significantly different. 38 In contrast, the NETest assay consistently outperformed the chromogranin A test in patients with carcinoid tumors. 40, 41, 45, 46 
Conclusion
Among the studies summarized in this analysis, there is a large variation in mutation detection and concordance with mutations found in tumor tissue (Table 3) . Overall, the research to date does not support the use of liquid biopsy as a surrogate to tissue-based biopsy. However, some assays, such as the NETest for NETs, may be useful as an adjunct to other tests for diagnosis; and CTC, cfDNA, and ctDNA markers may have some utility to follow the clinical course once a tumor is diagnosed and the somatic mutations in the neoplasm identified. 
